Economic Observation Network Publish mid-term positive data for the clinical trial of core product NGN-401, supporting its stock price at a high level. On June 30th, the company released the latest interim data from the Phase 1/2 clinical trial of its core product NGN-401 (for the treatment of Rett syndrome), which showed that all 10 subjects experienced clinical improvement and achieved an average of 4.7 new developmental milestones This positive data is the fundamental basis supporting its recent high stock price.

The above content is based on publicly available information and does not constitute investment advice.